NBE-002 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial evaluates a new treatment called NBE-002 to determine its safety and effectiveness for people with advanced solid tumors, including certain types of breast cancer. The study aims to identify the optimal dose for future treatments. Participants will receive varying doses of the drug to assess its impact on their condition. It suits those with advanced solid tumors who have not responded to other treatments and have a tumor that doctors can measure. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications. However, you cannot use systemic steroids above a certain dose or have had recent systemic anti-cancer treatments. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that NBE-002 is likely to be safe for humans?
Research has shown that NBE-002 is a new treatment being tested for safety and patient tolerance in those with advanced solid tumors. Early studies have examined how NBE-002 targets and kills cancer cells while sparing healthy ones.
Information on safety is still being gathered. As this trial is in its early stages (Phase 1/2), the primary goal is to assess patient tolerance. Researchers are carefully monitoring for any side effects or adverse reactions. So far, previous patients have tolerated NBE-002, but more data is needed to fully understand its safety.
The trial includes different groups receiving various doses to identify the optimal dose with the fewest side effects. If the treatment proves safe in these early stages, it could lead to more extensive testing later. Findings at this stage are crucial to ensuring the treatment's safety before proceeding further.12345Why do researchers think this study treatment might be promising?
Researchers are excited about NBE-002 because it offers a novel approach to treating advanced solid tumors. Unlike traditional therapies such as chemotherapy and radiation, which affect both cancerous and healthy cells, NBE-002 is designed to specifically target cancer cells. This targeted approach potentially reduces side effects and increases effectiveness. Additionally, NBE-002 employs an innovative mechanism that could work against tumors that are resistant to current treatments, providing new hope for patients with advanced stages of cancer.
What evidence suggests that NBE-002 could be an effective treatment for advanced solid tumors?
Research has shown that NBE-002, a treatment combining an antibody with a drug, holds promise for treating advanced solid tumors. Studies have found that it can slow tumor growth across various cancer types. In this trial, participants will receive NBE-002, which may be effective alone or in combination with common cancer treatments like carboplatin and paclitaxel. This treatment targets a protein called ROR1, often found in high levels in many cancers, suggesting it could be highly effective for tumors with this protein. Early results support its potential as a promising option for patients with advanced solid tumors.12678
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose-escalation
Participants receive escalating doses of NBE-002 to determine the recommended Phase 2 dose
Safety-expansion
Participants receive NBE-002 at doses determined from the dose-escalation phase to assess safety and tolerability
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- NBE-002
Find a Clinic Near You
Who Is Running the Clinical Trial?
NBE-Therapeutics AG
Lead Sponsor
Cmed Clinical Services
Collaborator